American Century Companies Inc. Has $46.10 Million Stock Position in Amgen Inc. $AMGN

American Century Companies Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 110.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 165,122 shares of the medical research company’s stock after buying an additional 86,815 shares during the quarter. American Century Companies Inc.’s holdings in Amgen were worth $46,104,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Management Group Inc. acquired a new position in shares of Amgen in the second quarter valued at approximately $385,000. Meridian Wealth Advisors LLC boosted its stake in Amgen by 0.6% in the 2nd quarter. Meridian Wealth Advisors LLC now owns 8,214 shares of the medical research company’s stock valued at $2,294,000 after purchasing an additional 49 shares during the period. WealthBridge Capital Management LLC grew its holdings in Amgen by 23.6% in the 2nd quarter. WealthBridge Capital Management LLC now owns 1,099 shares of the medical research company’s stock valued at $307,000 after buying an additional 210 shares in the last quarter. New World Advisors LLC increased its position in Amgen by 64.9% during the 2nd quarter. New World Advisors LLC now owns 1,159 shares of the medical research company’s stock worth $324,000 after buying an additional 456 shares during the period. Finally, Cozad Asset Management Inc. lifted its holdings in shares of Amgen by 22.0% during the second quarter. Cozad Asset Management Inc. now owns 2,133 shares of the medical research company’s stock worth $596,000 after buying an additional 384 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $344.65 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The stock has a market cap of $185.59 billion, a PE ratio of 28.18, a PEG ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $345.84. The business has a 50-day simple moving average of $307.51 and a two-hundred day simple moving average of $294.74.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period last year, the firm posted $5.58 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is 73.57%.

Wall Street Analyst Weigh In

A number of research firms recently commented on AMGN. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday. Guggenheim raised their target price on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Cantor Fitzgerald lifted their price target on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Morgan Stanley cut their price target on Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Finally, Wells Fargo & Company set a $400.00 price objective on Amgen in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $333.74.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.